Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Balixafortide TFA (POL6326 TFA) | 1051366-32-5 | 99.9% | 1978.16 | 25 MG
Balixafortide TFA (POL6326 TFA) is a potent, selective, and well-tolerated peptidic CXCR4 antagonist with an IC50 less than 10 nM. It demonstrates significant selectivity for CXCR4, approximately 1000-fold, over various other receptors including CXCR7. This compound effectively blocks β-arrestin recruitment and calcium flux with IC50s less than 10 nM, functioning as a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent with observed anti-cancer effects.
- Potent and selective CXCR4 antagonist
- Demonstrates high selectivity over other receptors like CXCR7
- Blocks β-arrestin recruitment and calcium flux
- Functions as a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent
- Exhibits anti-cancer effects
- Optimized for favorable mouse ADME properties
Medchemexpress LLC JBJ-09-063 (TFA) | 99.6% | 670.67 | 25 MG
JBJ-09-063 TFA is a mutant-selective allosteric EGFR inhibitor that effectively reduces EGFR, Akt, and ERK1/2 phosphorylation. It is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models and can be used for researching EGFR-mutant lung cancer. This inhibitor is remarkably effective at inhibiting cell growth, leading to a significant increase in apoptosis, and exhibits favorable pharmacokinetics properties for good efficacy upon oral dosing.
- Mutant-selective allosteric EGFR inhibitor
- Reduces EGFR, Akt, and ERK1/2 phosphorylation
- Effective against EGFR TKI-sensitive and resistant models
- Suitable for EGFR-mutant lung cancer research
- Inhibits cell growth and increases apoptosis
- Favorable pharmacokinetics properties
- Stable for good efficacy upon oral dosing
Medchemexpress LLC DAMGO TFA | 950492-85-0 | 99.5% | 627.61 | 25 MG
DAMGO TFA is a selective agonist for the μ-opioid receptor (μ-OPR) with a Kd of 3.46 nM for native μ-OPR. It significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, without down-regulating CXCR4 protein expression. It is for research use only.
- Effectively inhibits prostaglandin E2 (PGE2) induced increase in a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R INa).
- Produces significant anti-injury effects.
- Exhibits long-lasting analgesic effects in a dose-dependent manner.
Medchemexpress LLC Peptide5 TFA | 98.9% | 1509.60 | 1 MG
A connexin 43 mimetic peptide, it reduces animal swelling, astrogliosis, and neuronal cell death after spinal cord injury. It also inhibits NLRP3 inflammasome, and is an anti-inflammatory agent.
- Reduces animal swelling after spinal cord injury.
- Reduces astrogliosis after spinal cord injury.
- Reduces neuronal cell death after spinal cord injury.
- Inhibits NLRP3 inflammasome.
- Acts as an anti-inflammatory agent.
Medchemexpress LLC Ala-MPSD TFA | 98.02% | 3016.76 | 5 MG
Ala-MPSD TFA is a control peptide for MPSD (HY-P10471). In Ala-MPSD TFA, the four serine residues of MPSD are substituted by alanines.
- Control peptide for MPSD (HY-P10471)
- Four serine residues of MPSD are substituted by alanines
- Molecular formula: C147H243N41O27.XC2HF3O2
- Sequence: Lys-Lys-Lys-Lys-Lys-Arg-Phe-Ala-Phe-Lys-Lys-Ala-Phe-Lys-Leu-Ala-Gly-Phe-Ala-Phe-Lys-Lys-Asn-Lys-Lys
- Purity: 98.02% (HPLC)
- Appearance: White to off-white (solid)
- MS consistent with structure
Medchemexpress LLC MS15 TFA | C66H80F3N11O7S | 1 MG
MS15 TFA is a potent and selective PROTAC (proteolysis-targeting chimera) degrader that targets AKT. It effectively inhibits the activity of all three AKT isoforms (AKT1, AKT2, and AKT3) with varying potencies. This compound is suitable for research applications to study AKT's role in cellular processes.
- It is a potent and selective AKT PROTAC degrader.
- It inhibits AKT1 activity with an IC50 of 798 nM.
- It inhibits AKT2 activity with an IC50 of 90 nM.
- It inhibits AKT3 activity with an IC50 of 544 nM.
- It is bioavailable in mice through intraperitoneal administration.
- It is supplied as a solid with a white to yellow appearance.
- It is soluble in DMSO at concentrations of 100 mg/mL or higher.
TARGETMOL CHEMICALS INC CYN 154806 TFA 1MG
Also available in 5 mg, 10 mg, 25 mg, 50 mg, 100 mg and bulk. Please contact Fisher for quotes. CYN 154806 TFA is a cyclic octapeptide and an effective selective somatostatin sst2 receptor antagonist. For the recombinant sst2, sst1, sst3, sst4 and sst5 receptors, the pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48, respectively. Purity 99.7%
Medchemexpress LLC ATX-II TFA | 99.7% | 4934.62 (free acid) | 1 MG
ATX-II TFA is a selective sodium channel modulator toxin. It enhances late sodium current and prevents full sodium channel inactivation, leading to persistent current fractions. This can have pro-arrhythmic effects, such as slowing intrinsic heart rate and prolonging the QT interval. It is suitable for research on atrial fibrillation and long QT syndromes.
- Selective sodium channel modulator toxin
- Enhances late sodium current
- Prevents full sodium channel inactivation
- Generates persistent current fractions
- Has a pro-arrhythmic effect
- Slows intrinsic heart rate
- Prolongs QT interval
- Suitable for research on atrial fibrillation
- Suitable for research on long QT syndrome
- Purity of 99.7%
- Molecular weight of 4934.62 (free acid)
- Appearance as a solid
- White to off-white color
Medchemexpress LLC Sar441255 TFA | 99.9% | 4866.56 (free base) | 1 MG
SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. It demonstrates high potency with balanced activation of all three target receptors. This compound shows positive acute glucoregulatory effects in diabetic obese monkeys, indicating its potential for metabolic and endocrine disease research, particularly in areas like obesity and type 2 diabetes.
- Potent unimolecular peptide receptor triagonist.
- Displays high potency with balanced activation of three target receptors.
- Shows positive acute glucoregulatory effects in diabetic obese monkeys.
- Relevant for research in metabolic diseases, including obesity and type 2 diabetes.
Medchemexpress LLC Huwentoxin IV | 526224-73-7 | >98% | 1 MG
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibiting neuronal Nav1.7, Nav1.2, Nav1.3, and Nav1.4 with IC50s of 26, 150, 338, and 400 nM, respectively.
- Potent and selective sodium channel blocker
- Inhibits neuronal Nav1.7, Nav1.2, Nav1.3, and Nav1.4
- IC50s of 26, 150, 338, and 400 nM, respectively
Medchemexpress LLC ATX-II TFA | 99.7% | 4934.62 | 500 UG
ATX-II TFA is a selective sodium channel modulator toxin that enhances late sodium current, prevents full sodium channel inactivation, and generates persistent current fractions. It has a pro-arrhythmic effect, slowing intrinsic heart rate and prolonging QT interval. This compound is suitable for research on atrial fibrillation, long QT syndrome, and long QT3 syndrome.
Medchemexpress LLC Cys-PKHB1 TFA | 1487.88 | 10MG
Cys-PKHB1 TFA is a peptide conjugated to PKHB1, functioning as a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. It induces mitochondrial alterations, reactive oxygen species generation, and intracellular calcium accumulation, leading to calcium-dependent cell death in breast cancer cells. This compound also activates the immune system in breast cancer cells via immunogenic cell death.
- Conjugated peptide acting as a CD47 agonist
- Thrombospondin-1 peptide mimic
- Exhibits antitumor effects
- Induces mitochondrial alterations
- Promotes reactive oxygen species (ROS) generation
- Causes intracellular calcium (Ca+) accumulation
- Leads to calcium-dependent cell death in breast cancer cells
- Activates the immune system through immunogenic cell death
Medchemexpress LLC TP-5801 (TFA) | 99.6% | 641.48 | 100 MG
TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor with an IC50 of 1.40 nM, demonstrating anti-tumor activity. It inhibits TNK1-driven, BCR-ABL-driven, and IL-3-driven Ba/F3 cell growth, and TNK1-dependent L540 cell growth.
- Orally active
- Potent TNK1 inhibitor (IC50=1.40 nM)
- Demonstrates anti-tumor activity
- Inhibits growth of various cell lines (Ba/F3 and L540) relevant to TNK1-driven processes
- Shows efficacy in animal models, prolonging lifespan and inhibiting localized tumor growth without signs of toxicity
Medchemexpress LLC Pepinh-MYD TFA | 3388.03 (free base) | 1 MG
Pepinh-MYD TFA is a MyD88 inhibitor that contains a domain sequence from MyD88 TIR and a protein transduction sequence, enabling it to penetrate the cell membrane. It interferes with MyD88-mediated TLR signaling pathways, thereby inhibiting related immune responses.
- Includes a domain sequence from MyD88 TIR
- Contains a protein transduction sequence
- Penetrates the cell membrane
- Interferes with MyD88-mediated TLR signaling pathways
- Inhibits related immune responses
- Holds potential for studying the role of MyD88 in viral infections